人福医药：盐酸羟考酮片获批

Core Viewpoint - The approval of the drug registration certificate for Oxycodone Hydrochloride Tablets by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell the product in the Chinese market [1] Group 1: Company Developments - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for Oxycodone Hydrochloride Tablets, which are indicated for the relief of moderate to severe cancer pain [1] - The approved specifications for the Oxycodone Hydrochloride Tablets are 15mg and 30mg [1] - The company submitted the marketing authorization application in January 2024, which has been accepted, and the total R&D investment for this project has reached approximately 11 million RMB [1] Group 2: Industry Context - The approval of Oxycodone Hydrochloride Tablets positions the company to compete in the pain management market, particularly for cancer patients [1] - Beijing Huasu Pharmaceutical Co., Ltd. received a drug registration certificate for its 5mg Oxycodone Hydrochloride Tablets in May 2024, indicating a competitive landscape in the market [1]